NuPathe's Zelrix first transdermal patch for migraine to undergo FDA review
This article was originally published in Clinica
Executive Summary
The US FDA has accepted the new drug application (NDA) for Conshohocken, Pennsylvania-based NuPathe's Zelrix, the first transdermal patch for migraine ever reviewed by the agency.